4/19/2007

Best known for IV drips, Baxter International, has quietly entered the $1 billion potential market of stem cell research with a trial making use of its cell separation technology. The trial uses autologous stem cell therapy, which involves harvesting stem cells from the patient's own bone marrow, to repair oxygen-deprived heart tissue. The drug G-CSF is administered to stimulate the bone marrow to produce more stem cells.

Full Story:
Reuters

Related Summaries